Time has passed quietly, and 2021 is about to halfway through. Under the national strategy of "innovation-driven development", the innovative medicine industry is upgraded again, and people's demand for medical services is rising. It coincides that my country is in a period of historical opportunity to leap from a major pharmaceutical country to a powerful pharmaceutical country, and the pharmaceutical industry continues to have major events. The annual "Top Three 100 Pharmaceutical Industry Lists" will also be released one after another. They are the "Top 100 China Pharmaceutical Industry List" issued by the China Pharmaceutical Industry Information Center, and the "Top 100 China Pharmaceutical Industry Series" jointly issued by Minai and the Pharmaceutical Economic News. "List" and "China's Top 100 Pharmaceutical Research and Development Strengths" released by Yaozhi.com. According to the author's knowledge, this year's "China's Top 100 Pharmaceutical R&D Capabilities" will be released at the "Sixth China Pharmaceutical R&D Innovation Summit (PDI)", a series of activities of the Smart Expo held on August 20.
The three top 100 lists, together to build the industry's prosperity
China Pharmaceutical Industry Information Center-"Top 100 Chinese Pharmaceutical Industry"
The "Top 100 Chinese Pharmaceutical Industry List" published by the Pharmaceutical Industry Information Center is based on the annual China Pharmaceutical Statistics Annual Report of the Ministry of Industry and Information Technology of the People's Republic of China. It reflects the economic operation of China's pharmaceutical industry and is highly credible and authoritative in the industry. The main basis for the judgment is the "main business income" of the listed companies.
Mi Nei.com/Pharmaceutical Economics News-"China's Pharmaceutical Industry Top 100 Series List"
The "China Pharmaceutical Industry Top 100 Series List" released by Meinenet and Pharmaceutical Economic News focuses on the innovation driving force and professional promotion power of pharmaceutical industry enterprises. The innovation driving force is mainly judged from the comprehensive R&D indicators of enterprise R&D investment. Professional promotion power is the company’s market terminal sales data, accounting for 40% and 60% of the weight respectively (this indicator has been used since the last meeting, and the previous selection statistical indicator was only the company’s annual sales revenue, which shows that pharmaceutical research and development are getting more and more obtained. The attention of the industry).
Yaozhi.com and "China Pharmaceuticals"-"China's Top 100 Pharmaceutical R&D Strengths"
The "Top 100 Chinese Pharmaceutical R&D Strengths" released by Yaozhi.com focuses more on the innovation of enterprises. Comprehensive statistics are made on the company’s drug acceptance and approval status, pharmaceutical companies’ R&D investment funds, drug clinical trials completion status and patent layout, and other data related to R&D, excluding the influence of market and sales layout on the company.
(For "enterprises without R&D investment", the R&D investment score is merged into the acceptance and approval scores)
Three laws show the future of the industry
In addition, by comparing the distribution of companies in the three major lists in detail, three interesting patterns can be found:The same company, different rankings, different rankings。Through the analysis of the 100 companies on the list of the three major lists in 2020 (because there is no overall list in the “Top 100 Chinese Pharmaceutical Industry Series” of Meinenet in 2020, and the current pharmaceutical market in China is still dominated by chemical drugs, it is Replaced by "Top 100 Chinese Chemical Pharmaceutical Companies"), the repeat rate of the companies on the list is nearly 60%, and 39 companies are on the top three lists at the same time. These companies are mostly industry leaders, such as Hengrui Pharmaceuticals, Fosun Pharmaceuticals, Chia Tai Tianqing, and Renfu Pharmaceuticals are one of them. Taking Hengrui Medicine as an example, it is ranked 10/1/1 on the Top 100 Chinese Pharmaceutical Industry List (Information Center), the Top 100 Chinese Pharmaceutical Industry List (Minenet), and the Top 100 Chinese Pharmaceutical R&D Capabilities. The main reason for the difference in rankings among the lists may be mainly due to the rules and statistical scope of the list. Among them, the top 100 pharmaceutical industry in China (information center) mainly focuses on the revenue and scale of pharmaceutical companies, and also covers Many non-listed companies and multinational pharmaceutical companies; China’s top 100 pharmaceutical R&D strength list only judges the company’s pharmaceutical R&D strength, excluding the impact of revenue and net profit; while the China’s top 100 pharmaceutical industry list (Minenet) is an introduction. Between the two, there are statistics on sales data and R&D data, and multinational pharmaceutical companies are not included in the statistical scope. Therefore, because the three major lists have different focuses, the core meaning and value of the lists naturally have their own merits.
The three "single-listed" companies, with obvious differences
The "single-listed company" referred to here means that the company is only listed on one of the three lists, but not on the other two lists. According to the differences in the list of "single-listed companies", there are also obvious differences between the types of companies. Most of the “single-listed companies” in China’s Top 100 Pharmaceutical Industry (Information Center) are non-listed companies, joint ventures, pharmaceutical distribution companies, and established traditional Chinese medicine companies. Such companies are usually large in scale and have amazing revenue figures, but their products The gross profit margin and the severe homogeneity of products are also common characteristics. The operation mainly relies on its strong commercial layout, and the financial is usually characterized by sales expenses exceeding the industry average. Most of the “single-listed companies” in China’s top 100 drug R&D strengths list are members of innovative companies or emerging industries, because the scoring criteria are based on drug acceptance and approval, drug companies’ R&D investment funds, and drug clinical trials completion. Judging by various situations such as patent layout, such as BeiGene, Cinda Bio, Biotech, Watson Bio, CStone Pharmaceuticals, Rongchang Bio, etc., are all companies that have made outstanding contributions in the field of innovative drugs during 2019. It represents the rising star in China's innovative medicine field, and is also a "potential stock" that is expected to become a new generation of industry leaders in the future. The “single-listed companies” in China's Top 100 Pharmaceutical Industry List (Minenet) are mostly companies in the pharmaceutical industry that take into account both revenue and R&D. Most of these companies are typical representatives of "transformed companies" in the medical reform policy. They have invested a lot of money and energy in R&D transformation while maintaining a stable base of current revenue. After success, they can guarantee a great position in the industry. To a certain extent, it changes its core corporate positioning, but at the same time benefits come with the risk of failure in transformation. Haipurui, Yan'an Bikang, and Harbin Sanlian are among the representatives of its "single-listed enterprises". The R&D list a few years ago has a very high degree of familiarity with the current top 100 list. Finally, comparing the two top 100 pharmaceutical companies in the past, the ranking of a large number of innovative pharmaceutical companies has gradually risen, especially in recent years, which is similar to Hengrui and Fosun. The rankings of pharmaceutical companies such as pharmaceuticals have gradually entered the top ten, while the rankings of companies such as Buchang Pharmaceuticals and Tongrentang have declined year by year. However, as early as 2016, Fosun Pharma was already at the forefront of the list in the "China Pharmaceutical R&D Strength Rankings". This shows that the "China's pharmaceutical R&D strength rankings" have a certain predictability for the development of the industry. The innovative companies that are on the "China's top 100 pharmaceutical R&D strengths" are very hopeful that they will be listed in the "China's top 100 pharmaceutical industries". List (Minenet)" and "China's Pharmaceutical Industry Top 100 List (Information Center)". At the same time, it is also in line with the laws of today's pharmaceutical companies and R&D-driven industries.
A hundred schools of thought contend to build the industry's prosperity
In general, the "Three Top 100 Lists" of the pharmaceutical industry have their own characteristics and different core positioning. Through the three lists, one can gain insights into China's top 100 pharmaceutical companies from different perspectives, see benchmarks, and promote the accelerated development of enterprises. , To promote the industry's considerable progress. Today, the "Top 100 Chinese Pharmaceutical R&D Capabilities", one of the "Top 100 Pharmaceutical Industry Lists", will soon be released in the 2021 edition. When innovation is king in the pharmaceutical industry, it will undoubtedly be one of the most important annual events in 2021. , Click "Announcement of Conference Agenda! 100+ academicians, experts, and 1000+ pharmaceutical enterprise elites gathered at the 6th China Pharmaceutical Research and Development Innovation Summit (PDI)" for details.Attachment: 2020 version of the "Top Three 100 Pharmaceutical Industry List"
